The Motley Fool Discussion Boards

Previous Page

Investing/Strategies / New Paradigm Investing


Subject:  EXEL and Roche Date:  10/3/2012  8:11 PM
Author:  dumaflotchie Number:  63912 of 115174

Reading this article and the stated talents and focus of has to wonder if CABO might have found a potential partner in near future. I just don't see EXEL getting CABO to market by itself inclusive of all that is required outside of the science itself.

Sounds like Roche knows the business and can expedite the process.

Pure speculation of course but after reading this article, this sounds more encouraging to EXEL's opportunities......if it doesn't run out of money first.

Fortunately for Exelixis, GDC-0973 represents Roche's main effort to protect its melanoma franchise. This guarantees an aggressive and efficient development program for the drug. Roche is 6 months behind GSK, but positive results should enable it to retain its presence in melanoma from 2015 onwards. In parallel, GDC-0973 is in several early stage combination trials.

Market ignores a major milestone - a buying opportunity

Exelixis now has a second drug in pivotal studies, in development by a strong and committed partner. Roche's commitment, a large commercial opportunity, favorable deal terms and a high likelihood of clinical success, make GDC-0973 an important asset for Exelixis that is still not reflected in the company's valuation. This creates a buying opportunity, as the market will eventually acknowledge the opportunity as well as the strategic importance of GDC-0973 to Roche.

Copyright 1996-2019 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us